Jacquelyn N. Crane

Jacquelyn N. Crane

Auto-generated profile, based on publicly available information

Jacquelyn N. Crane

Children's Hospital of Philadelphia, Department of Pediatrics, Perelman School of Medicine University of Pennsylvania Philadelphia Pennsylvania USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2022 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
JCJacquelyn N. Crane
Jacquelyn N. Crane
WXWei Xue
Wei Xue
AQAmira Qumseya
Amira Qumseya
ZGZhengya Gao
Zhengya Gao
CACarola A. S. Arndt
Carola A. S. Arndt
AWAaron R. Weiss
Aaron R. Weiss

9 June 2023 in Sarcoma
Verified
Journal Article
Open access
PDF file
JCJacquelyn N. Crane
Jacquelyn N. Crane
DGDanielle S. Graham
Danielle S. Graham
CMChristine E. Mona
Christine E. Mona
SNScott D. Nelson
Scott D. Nelson
ASAlireza Samiei
Alireza Samiei
NFNoah C. Federman
Noah C. Federman
Objectives. Fibroblast activation protein alpha (FAP) is highly expressed by cancer-associated fibroblasts in multiple epithelial cancers. The aim of this study was to characterize FAP expression in sarcomas to explore its potential utility as a diagnostic and therapeutic target and prognostic biomarker in sarcomas. Methods. Available tissue samples from patients with bone or soft tissue tumors were identified at the University of California, Los Angeles. FAP expression was evaluated via immunohistochemistry (IHC) in tumor samples (n=63), adjacent normal tissues (n=30), and positive controls (n=2) using semiquantitative systems for intensity (0=negative; 1=weak; 2=moderate; and 3=strong) and density (none, 75) in stromal and tumor/nonstromal cells and using a qualitative overall score (not detected, low, medium, and high). Additionally, RNA sequencing data in publicly available databases were utilized to compare FAP expression in samples (n=10,626) from various cancer types and evaluate the association between FAP expression and overall survival (OS) in sarcoma (n=168). Results. The majority of tumor samples had FAP IHC intensity scores 2 and density scores 25 for stromal cells (77.7) and tumor cells (50.7). All desmoid fibromatosis, myxofibrosarcoma, solitary fibrous tumor, and undifferentiated pleomorphic sarcoma samples had medium or high FAP overall scores. Sarcomas were among cancer types with the highest mean FAP expression by RNA sequencing. There was no significant difference in OS in patients with sarcoma with low versus high FAP expression. Conclusion. The majority of the sarcoma samples showed FAP expression by both stromal and tumor/nonstromal cells. Further investigation of FAP as a potential diagnostic and therapeutic target in sarcomas is warranted.

28 June 2024 in Cancer
Verified
Journal Article
Closed access
JMJonathan Metts
Jonathan Metts
JAJamie M. Aye
Jamie M. Aye
JCJacquelyn N. Crane
Jacquelyn N. Crane
SOSapna Oberoi
Sapna Oberoi
FBFrank M. Balis
Frank M. Balis
CHChristine Heske
Christine Heske

2 December 2019 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
JCJacquelyn N. Crane
Jacquelyn N. Crane
VCVivian Y. Chang
Vivian Y. Chang
WYWilliam H. Yong
William H. Yong
NSNoriko Salamon
Noriko Salamon
HCHane Lee For Ucla Clinical Genomics Center
Hane Lee For Ucla Clinical Genomics Center
TDTom Davidson
Tom Davidson

12 December 2025 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
JCJacquelyn N Crane
Jacquelyn N Crane
WXWei Xue
Wei Xue
AQAmira Qumseya
Amira Qumseya
DBDonald A Barkauskas
Donald A Barkauskas
KCKhang Chau
Khang Chau
TLTheodore Laetsch
Theodore Laetsch
Background: The cornerstone of the treatment of malignant peripheral nerve sheath tumors is surgical resection. Radiation and chemotherapy are variably employed. The optimal treatment remains uncertain, particularly for unresectable or metastatic disease and patients with neurofibromatosis type 1 (NF-1). Methods: We present data for 58 patients with newly diagnosed malignant peripheral nerve sheath tumors enrolled on the Children’s Oncology Group study ARST0332. Patients were treated with risk-adapted therapy including surgery with or without radiotherapy and ifosfamide and doxorubicin chemotherapy. Results: Most patients had primary tumors that were greater than 5 cm (86%), deep (95%), and invasive (74%), and 10% had distant metastases. Of the patients, 32 (55%) had germline NF-1, and 26 (45%) did not. Among patients, 31 received neoadjuvant therapy, and 22 were evaluable for response with 5 (23%) attaining an objective response, 10 (45%) stable disease, and 7 (32%) progressive disease. Estimated 5-year event-free survival was 87%, 52%, and 0% for the low- (n = 8), intermediate-, (n = 44), and high-risk (n = 6) patients, respectively. In univariate analysis, event-free survival and overall survival differed by sex, presence or absence of metastatic disease, risk group, and achievement of upfront or delayed R0 and/or R1. There was no difference in event-free survival or overall survival based on germline NF-1 status. Conclusion: The treatment strategy in ARST0332 achieved excellent outcomes for low-risk malignant peripheral nerve sheath tumors. Patients with high-risk (metastatic) malignant peripheral nerve sheath tumors have poor outcomes, and novel treatments are needed (NCT00346164).